Fist10EM - February 17, 2020 - By Justin Morgentern
"Everyone knows about the CRASH-2 trial. It is now a decade old. It doesn’t seem like it desperately needs a new blog post, but I think that understanding this trial is important when trying to interpret the results of the newer CRASH-3 or WOMAN trials, and other TXA research that is on the horizon. So let’s review CRASH-2...
Bottom line
CRASH 2 demonstrated a 1.5% absolute reduction in mortality among trauma patients who were bleeding or at risk of bleeding. Although it is an excellent trial, it is not sacrosanct, and it’s various shortcomings need to be considered."